Rocuronium

Pharmacologic Category

Neuromuscular Blocker Agent, Nondepolarizing

Dosing: Adult

Note: Dose to effect; doses will vary due to interpatient variability. Ensure adequate pain control and sedation prior to and during administration of neuromuscular blockade to achieve deep sedation (SCCM [Murray 2016]).

Intensive care unit paralysis (eg, use for up to 48 hours in patients with early ARDS with PaO₂/FiO₂ <150, to facilitate mechanical ventilation, or for shivering from therapeutic hypothermia) (off-label dosing): Initial bolus of 0.6 to 1 mg/kg, followed by continuous IV infusion of 8 to 12 mcg/kg/minute (0.48 to 0.72 mg/kg/hour); monitor depth of blockade every 2 to 3 hours initially until stable dose, then every 8 to 12 hours; adjust rate of administration by 10% increments according to desired clinical response and possibly with peripheral nerve stimulation (Greenberg 2013; Rudis 1996; Spar 1997; SSCM [Murray 2002]; Warr 2011).

Note: When possible, minimize depth and duration of paralysis. Stopping the infusion for some time until forced to restart based on patient condition is recommended to reduce post-paralytic complications (eg, acute quadriplegic myopathy syndrome [AQMS]) (SSCM [Murray 2002; Murray 2016]).

Intermittent dosing: Initial loading dose: 50 mg followed by 25 mg given when peripheral nerve stimulation returns (Sparr 1997).

Neuromuscular blockade for endotracheal intubation, surgery, or mechanical ventilation (as adjunct to general anesthesia):

Rapid sequence intubation: IV: 0.6 to 1.2 mg/kg

Obesity: In adult patients with morbid obesity (BMI >40 kg/m²), the use of 1.2 mg/kg using ideal body weight (IBW) provided a short onset of action and excellent or good intubating conditions at 60 seconds in one study (Gaszynski 2011).

Tracheal intubation: IV:

Initial: 0.45 to 0.6 mg/kg; administration of 0.3 mg/kg may also provide optimal conditions for tracheal intubation (Barclay 1997)

Obesity: May use ideal body weight (IBW) for morbidly obese (BMI >40 kg/m²) adult patients (Leykin 2004; Meyhoff 2009); onset time may be slightly delayed using IBW. The manufacturer recommends dosing based on actual body weight in all obese patients.

Maintenance for continued surgical relaxation: 0.1 to 0.2 mg/kg; repeat as needed or a continuous infusion of 10 to 12 mcg/kg/minute (0.6 to 0.72 mg/kg/hour) only after recovery of neuromuscular function is evident; infusion rates have ranged from 4 to 16 mcg/kg/minute (0.24 to 0.96 mg/kg/hour)

Note: Inhaled anesthetic agents prolong the duration of action of rocuronium. Use lower end of the dosing range; redosing interval guided by monitoring with a peripheral nerve stimulator.

Preinduction defasciculation (off-label use): IV: 0.03 to 0.06 mg/kg given 1.5 to 3 minutes before administration of succinylcholine (Harvey 1998; Martin 1998)

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

No dosage adjustment necessary. Duration of neuromuscular blockade may vary in patients with renal impairment.

Dosing: Hepatic Impairment: Adult

No dosage adjustment provided in manufacturer’s labeling. However, dosage reductions may be necessary in patients with liver disease; duration of neuromuscular blockade may be prolonged due to increased volume of distribution. When rapid sequence intubation is required in adult patients with ascites, a dose on the higher end of the dosage range may be necessary to achieve adequate neuromuscular blockade.

Dosing: Obesity: Adult

Refer to indication-specific dosing for obesity-related information (may not be available for all indications). Ideal body weight or adjusted body weight is generally recommended when calculating dose for obese patients (SCCM [Murray 2016]).

Dosing: Pediatric

Note: Dose to effect; doses will vary due to interpatient variability. Dosing also dependent on anesthetic technique and age of patient. In general, the onset of effect is shortened and duration is prolonged as the dose increases. The time to maximum nerve block is shortest in infants 1 to 3 months; the duration of relaxation is shortest in children 2 to 11 years and longest in infants. The manufacturer recommends dosing based on actual body weight in all obese patients; however, some have recommended dosing based on ideal body weight (IBW) in obese patients (Playfor 2007).

Rapid sequence intubation: Children and Adolescents: IV: 0.9 to 1.2 mg/kg; Note: Lower doses of 0.6 mg/kg have been reported in the literature; however, some studies found this dosing resulted in prolonged time to onset, shortened duration of neuromuscular blockade and less favorable intubating conditions (Cheng 2002; Fuchs-Buder 1996; Mazurek 1998; Naguib 1997)

Tracheal intubation, surgical: Infants, Children, and Adolescents: Note: Inhaled anesthetic agents prolong the duration of action of rocuronium; use lower end of the dosing range; dosing interval guided by monitoring with a peripheral nerve stimulator.

Initial:

IV: 0.45 to 0.6 mg/kg

IM (Kaplan 1999): Limited data available: Note: Due to the prolonged time to onset in some patients, IM dosing may not be ideal for rapid sequence intubation for the general population and should be reserved to clinical scenarios when alternative agents are not appropriate.

Infants ≥3 months: 1 mg/kg administered as a single dose

Children 1 to 6 years: 1.8 mg/kg administered as a single dose

Maintenance for continued surgical relaxation:

Intermittent IV dosing: Infants, Children, and Adolescents: 0.075 to 0.15 mg/kg; repeat as needed

Continuous IV infusion: Infants, Children, and Adolescents: 7 to 12 mcg/kg/minute (0.42 to 0.72 mg/kg/hour); the manufacturer recommends using the lower end of the dosing range for infants and the upper end for children >2 to ≤11 years of age; higher doses have been reported with prolonged infusions (Tobias 1996)

Dosing: Renal Impairment: Pediatric

Infants, Children, and Adolescents: No dosage adjustment necessary; duration of neuromuscular blockade may vary in patients with renal impairment.

Dosing: Hepatic Impairment: Pediatric

Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, dosage reductions may be necessary in patients with liver disease; duration of neuromuscular blockade may be prolonged due to increased volume of distribution. When rapid sequence intubation is required in adult patients with ascites, a dose on the higher end of the dosage range may be necessary to achieve adequate neuromuscular blockade.

Calculations

• Body Mass Index
• CDC BMI for Age (Boys; 2 - 20 years)
• CDC BMI for Age (Girls; 2 - 20 years)
• Ideal Body Weight and Dosing Weight
• Ideal Body Weight Percentage

Use: Labeled Indications

Neuromuscular blockade for endotracheal intubation, surgery, or mechanical ventilation: As an adjunct to general anesthesia to facilitate rapid sequence and routine tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation in adequately sedated ICU patients

Note: Neuromuscular blockade does not provide pain control, sedation, or amnestic effects. Appropriate analgesic and sedative mediations should be used before and during administration of neuromuscular blockade to achieve deep sedation.

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Acute respiratory distress syndromeLevel of Evidence [G]

Based on the Society for Critical Care Medicine Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient, a neuromuscular blocker may be considered for short-term use (up to 48 hours) during the early course of acute respiratory distress syndrome (ARDS) in adults with PaO₂/FiO₂ <150 mmHg ^Ref. Some experts recommend that neuromuscular blockers be considered for short-term use (up to 48 hours) only in patients with ARDS and severe gas exchange abnormalities (PaO₂/FiO₂ ≤120 mmHg) ^Ref. Note: Only cisatracurium has been studied in patients with ARDS. Whether or not other neuromuscular blockers will yield similar results is unknown.

Intensive care unit paralysis:Level of Evidence [C, G]

Data from two pharmacodynamic and pharmacokinetic studies of rocuronium use in a limited number of patients in the ICU supports the use of rocuronium in this setting ^Ref. Additional data may be necessary to further define the role of rocuronium in ICU patients who require neuromuscular blockade.

Based on the 2002 and 2016 Society of Critical Care Medicine clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient, rocuronium is an effective and recommended agent among other neuromuscular blockers for select adequately sedated patients in the ICU who require neuromuscular blockade (eg, to facilitate mechanical ventilation).

Preinduction defasciculation:Level of Evidence [B]

Data from two prospective randomized double-blinded clinical trials in patients undergoing tracheal intubation administered rocuronium prior to administration of succinylcholine supports the use of rocuronium in the prevention of muscular fasciculations after succinylcholine administration ^Ref. Additional trials may be necessary to further define the role of rocuronium as an agent used for preinduction defasciculation.

Shivering due to therapeutic hypothermia following cardiac arrestLevel of Evidence [G]

Based on the Society for Critical Care Medicine Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient, a neuromuscular blocker may be used to manage overt shivering in therapeutic hypothermia following cardiac arrest.

Level of Evidence Definitions

Level of Evidence Scale

Clinical Practice Guidelines

Critical Care:

ACCM/SCCM/ASHP, “Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient,” January 2002

SCCM, “Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient,” 2016

“Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016,” March 2017

Administration: IV

May be given as a bolus injection (undiluted) or via a continuous infusion.

Administration: Injectable Detail

pH (undiluted): 4

Administration: Pediatric

Parenteral:

IM: Administer undiluted by rapid IM injection into the deltoid muscle (Kaplan 1999; Reynolds 1996)

IV: May be administered undiluted by rapid IV injection; or further diluted and infused as a continuous IV infusion

Storage/Stability

Store unopened/undiluted vials under refrigeration at 2°C to 8°C (36°F to 46°F); do not freeze. When stored at room temperature (25°C [77°F]), it is stable for 60 days; once opened, use within 30 days. Dilutions up to 5 mg/mL in 0.9% sodium chloride, dextrose 5% in water, 5% dextrose in sodium chloride 0.9%, or lactated Ringer's are stable for up to 24 hours at room temperature.

Preparation for Administration: Adult

May be diluted in D5NS, D5W, LR or NS at concentrations up to 5 mg/mL; use within 24 hours of preparation.

Preparation for Administration: Pediatric

Continuous IV infusion: Dilute with NS, D₅W, D₅NS or LR to a final concentration of 0.5 to 5 mg/mL; use within 24 hours of preparation

Compatibility

See Trissel’s IV Compatibility Database

Open Trissel's IV Compatibility

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to calm muscles during surgery.

• It is used to calm muscles while on a breathing machine.

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Severe injection site pain

• Burning

• Edema

• Irritation

• Arrhythmia

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

High alert medication:

Other safety concerns:

Contraindications

Hypersensitivity (eg, anaphylaxis) to rocuronium, other neuromuscular-blocking agents, or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Anaphylactoid/hypersensitivity reactions: Have been reported; immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during use.

• Neuromuscular cross-sensitivity: Cross-sensitivity with other neuromuscular-blocking agents may occur; use is contraindicated in patients with previous anaphylactic reactions to other neuromuscular blockers.

• Prolonged paralysis: Some patients may experience prolonged recovery of neuromuscular function after administration (especially after prolonged use). Patients should be adequately recovered prior to extubation. Other factors associated with prolonged recovery should be considered (eg, corticosteroid use, patient condition).

Disease-related concerns:

• Burn injury: Resistance may occur in burn patients (≥20% of total body surface area), usually several days after the injury, and may persist for several months after wound healing (Han 2009).

• Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure); onset of action may be delayed and duration of action may be prolonged.

• Conditions that may antagonize neuromuscular blockade (decreased paralysis): Respiratory alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, and muscle trauma may result in antagonism of neuromuscular blockade (ACCM/SCCM/ASHP [Murray 2002]; Greenberg 2013; Miller 2010; Naguib 2002).

• Conditions that may potentiate neuromuscular blockade (increased paralysis): Electrolyte abnormalities (eg, severe hypocalcemia, severe hypokalemia, hypermagnesemia), cachexia, neuromuscular diseases, metabolic acidosis, respiratory acidosis, Eaton-Lambert syndrome, and myasthenia gravis may result in potentiation of neuromuscular blockade (Greenberg 2013; Miller 2010; Naguib 2002).

• Hepatic impairment: Use with caution in patients with hepatic impairment; clinical duration may be prolonged.

• Pulmonary hypertension: Use with caution in patients with pulmonary hypertension; use may increase pulmonary vascular resistance worsening symptoms of right heart failure.

• Respiratory disease: Use with caution in patients with respiratory disease.

• Valvular heart disease: Use with caution in patients with valvular heart disease; use may increase pulmonary vascular resistance.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Elderly: Use with caution in the elderly, effects and duration are more variable.

• Immobilized patients: Resistance may occur in patients who are immobilized.

• Pediatric: Not recommended by the manufacturer for rapid sequence intubation in pediatric patients; however, it has been used successfully in clinical trials for this indication (Cheng 2002; Fuchs-Buder 1996; Mazurek 1998; Naguib 1997).

Other warnings/precautions:

• Appropriate use: Maintenance of an adequate airway and respiratory support is critical. Tolerance to rocuronium may develop. All patients should receive eye care including liberal use of lubricating drops, gel, or ointment and eyelids should remain closed during continuous neuromuscular blockade to protect against damage to the cornea (ulceration and drying).

• Experienced personnel: Should be administered by adequately trained individuals familiar with its use.

• Extravasation: If extravasation occurs, local irritation may ensue; discontinue administration immediately and restart in another vein.

• Risk of medication errors: Accidental administration may be fatal. Confirm proper selection of intended product, store vial so the cap and ferrule are intact and the possibility of selecting the wrong product is minimized, and ensure that the intended dose is clearly labeled and communicated, when applicable.

* See Cautions in AHFS Essentials for additional information.

Pregnancy Considerations

Adverse events were not observed in animal reproduction studies. Rocuronium crosses the placenta; umbilical venous plasma levels are ~18% of the maternal concentration following a maternal dose of 0.6 mg/kg (Abouleish 1994). The manufacturer does not recommend use for rapid sequence induction during cesarean section.

Breast-Feeding Considerations

Information related to rocuronium use and breast-feeding has not been located. If present in breast milk, oral absorption by a nursing infant would be expected to be minimal (Lee 1993).

Briggs' Drugs in Pregnancy & Lactation

• Rocuronium

Adverse Reactions

Frequency not always defined.

Cardiovascular: Increased peripheral vascular resistance (abdominal aortic surgery: 24%, frequency not defined during other procedures), tachycardia (≤5%; incidence greater in children), hypertension, transient hypotension

Hypersensitivity: Anaphylaxis

<1%, postmarketing, and/or case reports: Anaphylactoid reaction, asthma, cardiac arrhythmia, ECG abnormality, edema at insertion site, hiccups, nausea, pruritus, skin rash, vomiting

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• Neuromuscular-Blocking Agent Allergy

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Bacitracin (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Botulinum Toxin-Containing Products: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Bromperidol: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

CarBAMazepine: May decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. Risk C: Monitor therapy

Clindamycin (Topical): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk D: Consider therapy modification

Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Risk D: Consider therapy modification

CycloSPORINE (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

EPHEDrine (Systemic): May enhance the therapeutic effect of Rocuronium. Risk C: Monitor therapy

Fosphenytoin-Phenytoin: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Management: When initiating a non-depolarizing neuromuscular blocking agent (NMBA) in a patient receiving an inhalational anesthetic, initial NMBA doses should be reduced 15% to 25% and doses of continuous infusions should be reduced 30% to 60%. Risk D: Consider therapy modification

Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination. Risk C: Monitor therapy

Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination. Risk C: Monitor therapy

Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Local Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Exceptions: Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical). Risk C: Monitor therapy

Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Pholcodine: May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported. Risk C: Monitor therapy

Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk D: Consider therapy modification

Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk X: Avoid combination

Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Tetracyclines: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Thiazide and Thiazide-Like Diuretics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Trimebutine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Monitoring Parameters

Vital signs (heart rate, blood pressure, respiratory rate); degree of muscle paralysis (eg, presence of spontaneous movement, ventilator asynchrony, shivering, and consider use of a peripheral nerve stimulator with train of four monitoring along with clinical assessments)

In the ICU setting, prolonged paralysis and generalized myopathy, following discontinuation of agent, may be minimized by appropriately monitoring degree of blockade.

Advanced Practitioners Physical Assessment/Monitoring

Dosage and rate of administration should be individualized and titrated to the desired effect, according to relevant clinical factors, premedication, concomitant medication, age, and general condition of the patient. Ventilator support must be instituted and maintained until adequate respiratory muscle function and/or airway protection are assured. This drug is not an anesthetic or analgesic; pain must be treated with other agents. Continuous monitoring of vital signs, cardiac and respiratory status, and neuromuscular block (objective assessment with peripheral external nerve stimulator) are mandatory until full muscle tone has returned. Safety precautions must be maintained until full muscle tone has returned. It may take longer for return of muscle tone in obese or elderly persons or patients with renal or hepatic disease, myasthenia gravis, myopathy, other neuromuscular diseases, dehydration, electrolyte imbalance, or severe acid/base imbalance. Monitor for a prolonged QT interval in pediatric patients when used concomitantly with anesthetic agents.

Long-term use: Monitor level of neuromuscular blockade, skeletal muscle movement, and respiratory effort. Reposition patient and provide skin, mouth, and eye care every 2 to 3 hours while patient is sedated. Emotional and sensory support (auditory and environmental) should be provided.

Nursing Physical Assessment/Monitoring

Ventilator support must be instituted and maintained until adequate respiratory muscle function and/or airway protection are assured. This drug is not an anesthetic or analgesic; pain must be treated with other agents. Continuous monitoring of vital signs, cardiac and respiratory status, and neuromuscular block (objective assessment with peripheral external nerve stimulator) are mandatory until full muscle tone has returned. Safety precautions must be maintained until full muscle tone has returned. It may take longer for return of muscle tone in obese or elderly persons or patients with renal or hepatic disease, myasthenia gravis, myopathy, other neuromuscular diseases, dehydration, electrolyte imbalance, or severe acid/base imbalance.

Long-term use: Monitor level of neuromuscular blockade, skeletal muscle movement, and respiratory effort. Reposition patient and provide skin, mouth, and eye care every 2 to 3 hours while patient is sedated. Emotional and sensory support (auditory and environmental) should be provided.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous, as bromide:

Generic: 50 mg/5 mL (5 mL); 100 mg/10 mL (10 mL)

Solution, Intravenous, as bromide [preservative free]:

Generic: 50 mg/5 mL (5 mL); 100 mg/10 mL (10 mL)

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous:

Zemuron: 10 mg/mL ([DSC])

Generic: 10 mg/mL (5 mL, 10 mL)

Solution, Intravenous, as bromide:

Generic: 50 mg/5 mL (5 mL)

Anatomic Therapeutic Chemical (ATC) Classification

• M03AC09

Generic Available (US)

Yes

Pricing: US

Solution (Rocuronium Bromide Intravenous)

50 mg/5 mL (per mL): $0.84 - $3.93

100 mg/10 mL (per mL): $0.80 - $3.78

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Blocks acetylcholine from binding to receptors on motor endplate inhibiting depolarization

Pharmacodynamics/Kinetics

Onset of action:

Infants ≥3 months and Children: 30 seconds to 1 minute

Adults: Good intubation conditions within 1 to 2 minutes (depending on dose administered); maximum neuromuscular blockade within 4 minutes

Duration:

Infants: 3 to 12 months: 40 minutes

Children: 1 to 12 years: 26 to 30 minutes

Adults: ~30 minutes (with standard doses, increases with higher doses and inhalational anesthetic agents); hypothermia may prolong the duration of action

Distribution: V_d:

Children: 0.21 to 0.3 L/kg

Adults: 0.22 to 0.26 L/kg

Hepatic dysfunction: 0.53 L/kg

Renal dysfunction: 0.34 L/kg

Protein binding: ~30%

Metabolism: Minimally hepatic; 17-desacetylrocuronium (5% to 10% activity of parent drug)

Half-life elimination:

Alpha elimination: 1 to 2 minutes

Beta elimination:

Infants 3 to 12 months: 1.3 ± 0.5 hours

Children 1 to <3 years: 1.1 ± 0.7 hours

Children 3 to <8 years: 0.8 ± 0.3 hours

Adults: 1.4 to 2.4 hours

Hepatic impairment: 4.3 hours

Renal impairment: 2.4 hours

Excretion: Feces (31%); urine (26%) (Proost 2000)

Clearance: Pediatric patients:

Infants 3 to <12 months: 0.35 L/kg/hour

Children 1 to <3 years: 0.32 L/kg/hour

Children 3 to <8 years: 0.44 L/kg/hour

Pharmacodynamics/Kinetics: Additional Considerations

Renal function impairment: Patients with renal failure have clinical durations that are similar to but somewhat more variable than what is expected in patients with normal renal function.

Hepatic function impairment: Patients with clinically significant hepatic impairment had moderately prolonged clinical duration; patients with cirrhosis had increased V_d, prolonged plasma half-life, and >2.5 times the recovery time compared to patients with normal hepatic function.

Geriatric: Onset time and duration of action are slightly longer in elderly patients.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

No information available to require special precautions

Related Information

• Dosing Considerations for the Critically Ill Patient With Morbid Obesity
• Neuromuscular-Blocking Agents

Pharmacotherapy Pearls

Rocuronium is classified as an intermediate-duration neuromuscular-blocking agent. Do not mix in the same syringe with barbiturates. Rocuronium does not relieve pain or produce sedation.

Index Terms

ORG 9426; Rocuronium Bromide; Zemuron

FDA Approval Date

March 17, 1994

References

Abouleish E, Abboud T, Lechevalier T, et al, "Rocuronium (Org 9426) for Caesarean Section," Br J Anaesth, 1994, 73(3):336-41.[PubMed 7946860]

Barclay K, Eggers K, and Asai T, “Low-Dose Rocuronium Improves Conditions for Tracheal Intubation After Induction of Anaesthesia With Propofol and Alfentanil,” Br J Anaesth, 1997, 78(1):92-4.[PubMed 9059214]

Bartkowski RR, Witkowski TA, Azad S, et al, “Rocuronium Onset of Action: A Comparison With Atracurium and Vecuronium,” Anesth Analg, 1993, 77(3):574-8.[PubMed 8103649]

Cheng CA, Aun CST, and Gin T, “Comparison of Rocuronium and Suxamethonium for Rapid Tracheal Intubation in Children,” Paediatr Anaesth, 2002, 12(2):140-5.[PubMed 11882225]

Cheymol G, “Effects of Obesity on Pharmacokinetics: Implications for Drug Therapy,” Clin Pharmacokinet, 2000, 39(3):215-31.[PubMed 11020136]

Erstad BL, “Dosing of Medications in Morbidly Obese Patients in the Intensive Care Unit Setting,” Intensive Care Med, 2004, 30(1):18-32.[PubMed 14625670]

Fuchs-Buder T and Tassonyi E, “Intubating Conditions and Time Course of Rocuronium-Induced Neuromuscular Block in Children,” Br J Anaesth, 1996, 77(3):335-8.[PubMed 8949805]

Gaszynski TM, Szewczyk T. “Rocuronium for Rapid Sequence Induction in Morbidly Obese Patients: A Prospective Study for Evaluation of Intubation Conditions After Administration 1.2 mg kg^-1 Ideal Body Weight of Rocuronium,” Eur J Anaesthesiol, 2011, 28(8):609-11.[PubMed 21562423]

Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? Crit Care Med. 2013;41(5):1332-1344.[PubMed 23591211]

Han TH and Martyn JAJ. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus.Br J Anaesth. 2009, 102(1):55-60.[PubMed 19029093]

Harvey SC, Roland P, Bailey MK, et al, "A Randomized, Double-Blind Comparison of Rocuronium, d-Tubocurarine, and 'Mini-Dose' Succinylcholine for Preventing Succinylcholine-Induced Muscle Fasciculations," Anesth Analg, 1998, 87(3):719-22.[PubMed 9728861]

Kaplan RF, Uejima T, Lobel G, et al, “Intramuscular Rocuronium in Infants and Children: A Multicenter Study to Evaluate Tracheal Intubating Conditions, Onset, and Duration of Action,” Anesthesiology, 1999, 91(3):633-8.[PubMed 10485771]

Khuenl-Brady KS, Sparr H, Puhringer F, et al, “Rocuronium Bromide in the ICU: Dose Finding and Pharmacokinetics,” Eur J Anaesthesiol Suppl, 1995, 11:79-80.[PubMed 8557012]

Kumar P, Denson SE, Mancuso TJ; Committee on Fetus and Newborn, Section on Anesthesiology and Pain Medicine. Premedication for nonemergency endotracheal intubation in the neonate. Pediatrics. 2010;125(3):608-615.[PubMed 20176672 ]

Lee JJ and Rubin AP, "Breast Feeding and Anaesthesia," Anaesthesia, 1993, 48(7):616-25.[PubMed 8346780]

Leykin Y, Pellis T, Lucca M, et al, “The Pharmacodynamic Effects of Rocuronium When Dosed According to Real Body Weight or Ideal Body Weight in Morbidly Obese Patients,” Anesth Analg, 2004, 99(4):1086-9.[PubMed 15385355]

Martin LD, Bratton SL, and O'Rourke PP, “Clinical Uses and Controversies of Neuromuscular Blocking Agents in Infants and Children,” Crit Care Med, 1999, 27(7):1358-68.[PubMed 10446832]

Martin R, Carrier J, Pirlet M, et al, "Rocuronium is the Best Non-Depolarizing Relaxant to Prevent Succinylcholine Fasciculations and Myalgia," Can J Anaesth, 1998, 45(6):521-5.[PubMed 9669004]

Mazurek AJ, Rae B, Hann S, et al, “Rocuronium versus Succinylcholine: Are They Equally Effective During Rapid-Sequence Induction of Anesthesia?” Anesth Analg, 1998, 87:1259-62.[PubMed 9842809]

Meretoja OA, Taivainen T, Jalkanen L, et al, “Synergism Between Atracurium and Vecuronium in Infants and Children During Nitrous Oxide-Oxygen-Alfentanil Anaesthesia,” Br J Anaesth, 1994, 73(5):605-7.[PubMed 7826787]

Meyhoff CS, Lund J, Jenstrup MT, et al. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth Analg. 2009;109(3):787-792.[PubMed 19690247]

Miller RD, Miller’s Anesthesia, 7th ed, Philadelphia PA: Churchill Livingstone, 2010.

Murray MJ, Cowen J, DeBlock H, et al, “Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians,” Crit Care Med, 2002, 30(1):142-56.[PubMed 11902255]

Murray MJ, DeBlock H, Erstad B, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2016;44(11):2079-2103. doi: 10.1097/CCM.0000000000002027.[PubMed 27755068]

Naguib M, Flood P, McArdle JJ, et al. Advances in neurobiology of the neuromuscular junction. Implications for the anesthesiologist. Anesthesiology. 2002; 96(1): 202-31.[PubMed 11753022]

Naguib M, Samarkandi AH, Ammar A, et al, “Comparison of Suxamethonium and Different Combinations of Rocuronium and Mivacurium for Rapid Tracheal Intubation in Children,”Br J Anaesth, 1997, 79(4):450-5.[PubMed 9389261]

Playfor S, Jenkins I, Boyles C, et al. Consensus guidelines for sustained neuromuscular blockade in critically ill children. Paediatr Anaesth. 2007;17(9):881-887.[PubMed 17683408 ]

Proost JH, Eriksson LI, Mirakhur RK, et al. Urinary, biliary and faecal excretion of rocuronium in humans. Br J Anaesth. 2000 Nov;85(5):717-723.[PubMed 11094587]

Puhringer FK, Khuenl-Brady KS, and Mitterschiffthaler G, “Rocuronium Bromide: Time-Course of Action in Underweight, Normal Weight, Overweight and Obese Patients,” Eur J Anaesthesiol Suppl, 1995, 11:107-10.[PubMed 8556996]

Reynolds LM, Lau M, Brown R, et al, “Bioavailability of Intramuscular Rocuronium in Infants and Children,” Anesthesiology, 1997, 87(5):1096-105.[PubMed 9366462]

Reynolds LM, Lau M, Brown R, Luks A, Fisher DM. Intramuscular rocuronium in infants and children. Dose-ranging and tracheal intubating conditions. Anesthesiology. 1996;85(2):231-239.[PubMed 8712436]

Rocuronium bromide [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; March 2019.

Rudis MI, Guslits BG, and Zarowitz BJ, “Technical and Interpretive Problems of Peripheral Nerve Stimulation in Monitoring Neuromuscular Blockade in the Intensive Care Unit,” Ann Pharmacother, 1996, 30(2):165-72.[PubMed 8835051]

Siegel MD. Acute respiratory distress syndrome: Supportive care and oxygenation in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed February 15, 2018.

Sparr HJ, Wierda JM, Proost JH, et al, “Pharmacodynamics and Pharmacokinetics of Rocuronium in Intensive Care Patients,” Br J Anaesth, 1997, 78(3):267-73.[PubMed 9135303]

Tobias JD. Continuous infusion of rocuronium in a paediatric intensive care unit. Can J Anaesth. 1996;43(4):353-357.[PubMed 8697549 ]

Warr J, Thiboutot Z, Rose L, et al, “Current Therapeutic Uses, Pharmacology, and Clinical Considerations of Neuromuscular Blocking Agents for Critically Ill Adults,” Ann Pharmacother, 2011, 45(9):1116-26.[PubMed 21828347]

Willets LS, “Rocuronium for Tracheal Intubation,” Ped Pharmacotherapy, 2000, 6(10):1-6.

Zemuron (rocuronium) [prescribing information]. Whitehouse Station, NJ: Merck & Co Inc; July 2018.

Brand Names: International

Curionialis (MX); Desproxyl (CR, DO, GT, HN, MX, NI, PA, SV); Eslax (JP); Esmeron (AE, AT, AU, BE, BG, BH, BR, CH, CL, CN, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IQ, IR, IS, IT, JO, KR, LB, LK, LT, LU, LV, LY, MT, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PT, RO, RU, SA, SE, SG, SI, SK, SV, SY, TH, TR, TW, UA, VE, VN, YE); Noveron (PH); Rocon (AU); Rocoron (LB); Rocum (ID); Rocumeron (KR); Rocur (UY); Rocuron (BD); Rocuronio (CO); Rocuthesia (EG); Romeron (KR); Zemuron (AR)

Last Updated 2/20/20